BARCELONA, Spain– INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company developing graphene-based neural technologies, today announced a collaboration agreement with Mayo Clinic aimed at accelerating the development and commercialization of INBRAIN’s precision BCI-Tx platform for patients with neurological disorders.
The agreement establishes a non-exclusive know-how exchange, with INBRAIN and Mayo Clinic experts working together in IRB-approved settings to evaluate the company’s investigational BCI-Tx system. The goal is to generate high-quality clinical evidence and advance patient-focused brain-computer interface therapeutics.
“Our goal is to translate the unique performance of graphene and AI to deliver benefits for patients and clinicians,” said Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics. “With Mayo Clinic’s clinical know-how, alongside other leading U.S. and European centers, we seek to validate our platform in real-world workflows, accelerate evidence generation, and move responsibly toward patient-focused BCI therapeutics.”
As part of its U.S. expansion, INBRAIN announced the formation of a subsidiary that will open offices in Boston and on the West Coast, while maintaining its global headquarters and R&D operations in Barcelona. The Boston office will act as a hub for U.S.-based clinical trials and support future commercialization of the company’s BCI-Tx platform beyond Parkinson’s disease. INBRAIN is also advancing scalable manufacturing processes for its graphene-based system to enable broader clinical and commercial adoption.
To date, INBRAIN has raised $124 million from a global syndicate of medtech and deeptech investors, including Aliath Bioventures, Asabys Partners, CDTI, Catalan Government (Avançsa & ICF), FondICO, Graybella Capital, IMECXpand, Mayo Clinic, the European Innovation Council, Truventuro, and Vsquared Ventures.
Mayo Clinic has a financial interest in the technology referenced in this announcement and will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
